<DOC>
	<DOCNO>NCT01444677</DOCNO>
	<brief_summary>The purpose study investigate safety tolerability MB12066 single multiple oral dose investigate pharmacokinetic characteristic MB12066 single multiple oral dose .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetic Study MB12066 Healthy Volunteers</brief_title>
	<detailed_description>- Safety/ Tolerability evaluation Adverse event , Physical examination , Vital sign , ECG ( include continuous ECG monitoring ) , Laboratory test ( include hematology , chemistry , coagulation , PBS , NAD ( P ) +/NAD ( P ) H ratio , urinalysis ) , CIC - Pharmacokinetic Evaluation ( single ) - Serial blood sample urine collection pharmacokinetic evaluation conduct 0 ( pre-dose ) 96 hour single oral dose . - Blood sampling time pre-dose , 0.5 , 1h , 2h , 3h , 4h , 6h , 8h , 10h , 12h , 16h , 24h , 36h , 48h , 72h post-dose - Urine collection time 0h - 6h , 6h - 12h , 12h - 24h , 24h - 48h , 48h - 72h - Evaluation parameter AUClast , AUCinf , Cmax , Tmax , t1/2 , Vd/F , CL/F , Ae , fe , CLR - Pharmacokinetic Evaluation ( multiple ) - Serial blood sample urine collection pharmacokinetic evaluation conduct single oral dose Steady state . - Blood sampling time Day 1 pre-dose , 0.5h , 1h , 2h , 3h , 4h , 6h , 8h , 10h , 12h , 16h , 24h , Day3-6 Pre-dose , Day7 Pre-dose , 0.5h , 1h , 2h , 3h , 4h , 6h , 8h , 10h , 12h , 16h , 24h , 36h , 48h , 72h , 96h post-dose - Urine collection time Day 1 Pre-dose , 0h - 6h , 6h - 12h , 12h - 24h , Day 7 Pre-dose , 0h - 6h , 6h - 12h , 12h - 24h - Evaluation parameter Cmax , s , Cmin , s , Cav , s , AUCτ , Tmax , s , t1/2 , PTF ( peak trough fluctuation ratio ) , fe , CLss/F , CLR</detailed_description>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Beta-lapachone</mesh_term>
	<criteria>1 . Subject inform investigational nature study voluntarily agree participate study sign Institutional Review Board ( IRB ) approve informed consent prior perform screen procedure 2 . Healthy Korean male volunteer , age range 20 45 year ( inclusive ) 3 . A subject body weight 60 kg ( inclusive ) 90 kg ( exclusive ) body mass index ( BMI ) 18.5 ( inclusive ) 25 ( exclusive ) . ☞ BMI ( kg/m2 ) = weight ( kg ) / { height ( ) } 2 4 . Findings within range clinical acceptability medical history physical examination , laboratory result within laboratory reference range relevant laboratory test ( unless investigator considers deviation irrelevant purpose study ) 1 . A subject history allergy include drug allergy ( aspirin , antibiotic , etc . ) , history clinically significant allergy 2 . A subject clinical evidence history hepatic ( include carrier hepatitis virus ) , renal , respiratory , endocrine , neurologic , immunologic , hematologic , oncologic , psychiatric , cardiovascular disease 3 . A subject history gastrointestinal disease surgery ( except simple appendectomy repair hernia ) , influence absorption study drug 4 . A subject whose hemoglobin ( Hb ) level &lt; 12 g/dL 5 . A subject fasting plasma glucose ( FPG ) level ≤ 70 mg/dL ≥ 126 mg/dL 6 . A subject HbA1c level ≥ 7.0 % 7 . A subject whose systolic blood pressure ( SBP ) ≤ 90 mmHg ≥ 140 mmHg , diastolic blood pressure ( DBP ) ≤ 40 mmHg ≥ 90 mmHg pulse rate ( PR ) ≥ 100 /min least 5 min sit 8 . A subject history drug abuse positive urine drug screen test 9 . A subject take prescribed medication herbal compound within 14 day prior study drug administration . In addition , subject take overthecounter drug vitamin supplement within 7 day prior study drug administration ( However , investigator judge subject , take medication period , eligible trial condition satisfy . ) 10 . A subject participate clinical trial either investigational market drug within 8 week study drug administration 11 . A subject donated loss ≥ 400 mL blood within 8 week prior start administration study drug 12 . A subject consumes 21 unit alcohol per week unable stop drinking throughout study period . 13 . A smoker ( except quit smoking prior drug administration least 3 month ) 14 . A subject heavily take caffeine caffeinecontaining product , grapefruit , grapefruit juice , grapefruitcontaining product 15 . A subject unusual dietary habit 16 . A subject previously assign treatment study 17 . The investigator judge subject eligible study review clinical laboratory result reason .</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetic</keyword>
</DOC>